Monika A Golinska

Monika A Golinska


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in Cells
Verified
Journal Article
Open access
PDF file
Shen-Han LeeShen-Han Lee
Shen-Han Lee
MGMonika A Golinska
Monika A Golinska
JGJohn Griffiths
John Griffiths
In solid tumours, cancer cells exist within hypoxic microenvironments, and their metabolic adaptation to this hypoxia is driven by HIF-1 transcription factor, which is overexpressed in a broad range of human cancers. HIF inhibitors are under pre-clinical investigation and clinical trials, but there is evidence that hypoxic cancer cells can adapt metabolically to HIF-1 inhibition, which would provide a potential route for drug resistance. Here, we review accumulating evidence of such adaptions in carbohydrate and creatine metabolism and other HIF-1-independent mechanisms that might allow cancers to survive hypoxia despite anti-HIF-1 therapy. These include pathways in glucose, glutamine, and lipid metabolism; epigenetic mechanisms; post-translational protein modifications; spatial reorganization of enzymes; signalling pathways such as Myc, PI3K-Akt, 2-hyxdroxyglutarate and AMP-activated protein kinase (AMPK); and activation of the HIF-2 pathway. All of these should be investigated in future work on hypoxia bypass mechanisms in anti-HIF-1 cancer therapy. In principle, agents targeted toward HIF-1β rather than HIF-1α might be advantageous, as both HIF-1 and HIF-2 require HIF-1β for activation. However, HIF-1β is also the aryl hydrocarbon nuclear transporter (ARNT), which has functions in many tissues, so off-target effects should be expected. In general, cancer therapy by HIF inhibition will need careful attention to potential resistance mechanisms.

11 April 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
Isabel Quiros-GonzalezIsabel Quiros-Gonzalez
Isabel Quiros-Gonzalez
MTMichal R Tomaszewski
Michal R Tomaszewski
MGMonika A Golinska
Monika A Golinska
EBEmma Brown
Emma Brown
LALaura Ansel-Bollepalli
Laura Ansel-Bollepalli
SBSarah Elizabeth Bohndiek
Sarah Elizabeth Bohndiek
Angiogenesis is an established prognostic factor in advanced breast cancer, yet response to antiangiogenic therapies in this disease remains highly variable. Noninvasive imaging biomarkers could help identify patients that will benefit from antiangiogenic therapy and provide an ideal tool for longitudinal monitoring, enabling dosing regimens to be altered with real-time feedback. Photoacoustic tomography (PAT) is an emerging imaging modality that provides a direct readout of tumor hemoglobin concentration and oxygenation. We hypothesized that PAT could be used in the longitudinal setting to provide an early indication of response or resistance to antiangiogenic therapy. To test this hypothesis, PAT was performed over time in estrogen receptor–positive and estrogen receptor–negative breast cancer xenograft mouse models undergoing treatment with the antiangiogenic bevacizumab as a single agent. The cohort of treated tumors, which were mostly resistant to the treatment, contained a subset that demonstrated a clear survival benefit. At endpoint, the PAT data from the responding subset showed significantly lower oxygenation and higher hemoglobin content compared with both resistant and control tumors. Longitudinal analysis revealed that tumor oxygenation diverged significantly in the responding subset, identifying early treatment response and the evolution of different vascular phenotypes between the subsets. Responding tumors were characterized by a more angiogenic phenotype when analyzed with IHC, displaying higher vessel density, yet poorer vascular maturity and elevated hypoxia. Taken together, our findings indicate that PAT shows promise in providing an early indication of response or resistance to antiangiogenic therapy. Significance: Photoacoustic assessment of tumor oxygenation is a noninvasive early indicator of response to bevacizumab therapy, clearly distinguishing between control, responding, and resistant tumors within just a few weeks of treatment.

29 August 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MGMonika A Golinska
Monika A Golinska
MWMaria Wołyniak
Maria Wołyniak
PKPiotr Kulesza
Piotr Kulesza
WFWojciech Fendler
Wojciech Fendler
Chronic pain is a defining feature of endometriosis and contributes significantly to the diminished quality of life observed in affected individuals. Despite advances in understanding disease pathology, current therapeutic strategies largely fail to simultaneously target both lesion development and pain generation. In this review, we examine the neurobiology of endometriosis-associated pain at the level of the brain, dorsal root ganglia, and lesion innervation, with a particular focus on the interplay between inflammation and neurogenesis. We highlight how these processes converge on the JAK/STAT signaling pathway, a critical regulator of both immune activation and nerve fiber growth. The central role of mast cells in coordinating inflammatory and neurogenic responses is also discussed. Emerging evidence supporting the use of JAK inhibitors and mast cell stabilizers in modulating these pathways is reviewed, with emphasis on their potential for repurposing in endometriosis therapy. By targeting the shared mechanisms underlying lesion progression and pain, these pharmacological strategies offer a promising avenue for improving clinical outcomes. Further research is necessary to validate the efficacy and safety of these approaches, but the therapeutic potential of JAK/STAT pathway inhibition and mast cell stabilization could represent a paradigm shift in endometriosis management.

8 July 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MGMonika A Golinska
Monika A Golinska
ARAleksander Rycerz
Aleksander Rycerz
MSMatylda Sobczak
Matylda Sobczak
JCJedrzej Chrzanowski
Jedrzej Chrzanowski
KSKonrad Stawiski
Konrad Stawiski
WFWojciech Fendler
Wojciech Fendler
Background: Molecular events that drive endometriosis (EM) and cause accompanying immune deregulation remain elusive. Our purpose was to identify key pathways involved in lesion formation across diverse populations and to detect transcriptomic changes in eutopic endometrium that accompany EM.Methods: We searched Gene Expression Omnibus and ArrayExpress and performed differential gene expression analysis and a network meta-analysis on nine qualifying datasets. Those contained transcriptomic data on 114 ectopic endometrium samples (EL), 138 eutopic endometrium samples from women with endometriosis (EEM), and 79 eutopic endometrium samples from women without endometriosis (EH). Gene ontology and enrichment analysis were performed in DAVID, Metascape, and Cytoscape, and drug repurposing was done in CMap.Results: EEM compared to EH upregulated CCL21 and downregulated BIRC3, CEL, and LEFTY1 genes (|log2FC| > 0.5, p < 0.05). EL showed increased expression of complement and serpin genes (EL vs. EEM: C7, logFC = 3.38, p < 0.0001; C3, logFC = 2.40, p < 0.0001; SERPINE1, logFC = 1.02, p < 0.05; SERPINE2, logFC = 1.54, p < 0.001) and mast cell markers (EL vs. EEM: CPA3, logFC = 1.54, p < 0.0001; KIT, logFC = 0.74, p < 0.001). Functional enrichment analysis highlighted complement and coagulation, inflammation, angiogenesis, and extracellular matrix remodeling as drivers of endometriosis. Pharmacogenomic analysis indicated Janus kinase (JAK), cyclin-dependent kinase (CDK), and topoisomerase inhibitors as therapy targets.Conclusion: Our results suggest an interplay between complement and coagulation, mast cells, extracellular matrix remodeling, and the JAK/STAT3 pathway in endometriosis. We underscore the significance of complement C3 and propose JAK inhibitors as therapy candidates. Detected expression differences between EEM and EH are important for the development of diagnosis via endometrial biopsy.

1 June 2024 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
JGJanek Gröhl
Janek Gröhl
KYKylie Yeung
Kylie Yeung
KGKevin Gu
Kevin Gu
TEThomas R. Else
Thomas R. Else
MGMonika A Golinska
Monika A Golinska
SBSarah Elizabeth Bohndiek
Sarah Elizabeth Bohndiek
Blood oxygen saturation (sO2) is an important indicator of individual health status used routinely in patient management.1 Photoacoustic (PA) imaging (PAI) is a promising medical imaging modality for real-time non-invasive spatially resolved measurement of sO2,2 with early clinical applications3 shown in, for example, inflammatory bowel disease4 and cardiovascular diseases.5 In cancer, alterations in localized sO2 levels have been linked to angiogenesis and hypoxia,6 the key hallmarks of cancer that are known to affect treatment outcomes7 and are measurable through PAI.

20 June 2024 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MOMariam-Eleni Oraiopoulou
Mariam-Eleni Oraiopoulou
DCDominique-Laurent Couturier
Dominique-Laurent Couturier
EBEllie V. Bunce
Ellie V. Bunce
ICIan G. Cannell
Ian G. Cannell
PSPaul W. Sweeney
Paul W. Sweeney
SBSarah Elizabeth Bohndiek
Sarah Elizabeth Bohndiek
Background/Objectives: Pseudo-vascular network formation in vitro is considered a key characteristic of vasculogenic mimicry. While many cancer cell lines form pseudo-vascular networks, little is known about the spatiotemporal dynamics of these formations. Methods: Here, we present a framework for monitoring and characterising the dynamic formation and dissolution of pseudo-vascular networks in vitro. The framework combines time-resolved optical microscopy with open-source image analysis for network feature extraction and statistical modelling. The framework is demonstrated by comparing diverse cancer cell lines associated with vasculogenic mimicry, then in detecting response to drug compounds proposed to affect formation of vasculogenic mimics. Dynamic datasets collected were analysed morphometrically and a descriptive statistical analysis model was developed in order to measure stability and dissimilarity characteristics of the pseudo-vascular networks formed. Results: Melanoma cells formed the most stable pseudo-vascular networks and were selected to evaluate the response of their pseudo-vascular networks to treatment with axitinib, brucine and tivantinib. Tivantinib has been found to inhibit the formation of the pseudo-vascular networks more effectively, even in dose an order of magnitude less than the two other agents. Conclusions: Our framework is shown to enable quantitative analysis of both the capacity for network formation, linked vasculogenic mimicry, as well as dynamic responses to treatment.